Leland Gershell
Stock Analyst at Oppenheimer
(4.54)
# 278
Out of 5,043 analysts
141
Total ratings
50.38%
Success rate
29.23%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Maintains: Outperform | $32 → $36 | $23.17 | +55.37% | 7 | Oct 21, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $73 → $87 | $42.06 | +106.85% | 8 | Sep 30, 2025 | |
| TECX Tectonic Therapeutic | Initiates: Outperform | $80 | $17.88 | +347.43% | 1 | Sep 3, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $7 → $8 | $9.23 | -13.33% | 3 | Aug 8, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $110 | $68.66 | +60.21% | 9 | Aug 7, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $60 → $61 | $64.50 | -5.43% | 3 | Aug 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Outperform | $490 | $475.98 | +2.95% | 8 | Aug 4, 2025 | |
| LXEO Lexeo Therapeutics | Initiates: Outperform | $20 | $10.08 | +98.41% | 1 | Jul 31, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $76 → $110 | $113.46 | -3.05% | 2 | Jul 10, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Outperform | $43 → $22 | $6.18 | +255.99% | 5 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $215 → $224 | $204.49 | +9.54% | 12 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $31 | $20.18 | +53.62% | 11 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $2.08 | +380.77% | 1 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $704 → $708 | $836.39 | -15.35% | 7 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $1.73 | +478.03% | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $20 | $10.54 | +89.75% | 3 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $98 | $53.49 | +83.21% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $52 | $33.65 | +54.53% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $50 | $3.67 | +1,264.26% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $21.98 | +141.13% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $7.81 | +284.12% | 2 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.00 | +300.00% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30,000 → $5,000 | $4.20 | +118,947.62% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $5.09 | +391.16% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $3.11 | +543.09% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $21.36 | +35.77% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $18.38 | +90.42% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.74 | +1,255.93% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $0.93 | +2,043.62% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $1.83 | +610.38% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $120 | $3.81 | +3,049.61% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $9.37 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $19.78 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $1.56 | +3,105.13% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $18.95 | - | 5 | Mar 31, 2020 |
Viridian Therapeutics
Oct 21, 2025
Maintains: Outperform
Price Target: $32 → $36
Current: $23.17
Upside: +55.37%
Crinetics Pharmaceuticals
Sep 30, 2025
Maintains: Outperform
Price Target: $73 → $87
Current: $42.06
Upside: +106.85%
Tectonic Therapeutic
Sep 3, 2025
Initiates: Outperform
Price Target: $80
Current: $17.88
Upside: +347.43%
Xeris Biopharma Holdings
Aug 8, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $9.23
Upside: -13.33%
Soleno Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $105 → $110
Current: $68.66
Upside: +60.21%
BridgeBio Pharma
Aug 6, 2025
Maintains: Outperform
Price Target: $60 → $61
Current: $64.50
Upside: -5.43%
Alnylam Pharmaceuticals
Aug 4, 2025
Upgrades: Outperform
Price Target: $490
Current: $475.98
Upside: +2.95%
Lexeo Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $20
Current: $10.08
Upside: +98.41%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Outperform
Price Target: $76 → $110
Current: $113.46
Upside: -3.05%
Capricor Therapeutics
Jun 23, 2025
Maintains: Outperform
Price Target: $43 → $22
Current: $6.18
Upside: +255.99%
Jun 13, 2025
Maintains: Outperform
Price Target: $215 → $224
Current: $204.49
Upside: +9.54%
Jun 13, 2025
Maintains: Outperform
Price Target: $10 → $31
Current: $20.18
Upside: +53.62%
Jun 6, 2025
Initiates: Outperform
Price Target: $10
Current: $2.08
Upside: +380.77%
May 9, 2025
Maintains: Outperform
Price Target: $704 → $708
Current: $836.39
Upside: -15.35%
Mar 24, 2025
Initiates: Outperform
Price Target: $10
Current: $1.73
Upside: +478.03%
Mar 11, 2025
Maintains: Outperform
Price Target: $12 → $20
Current: $10.54
Upside: +89.75%
Feb 24, 2025
Upgrades: Outperform
Price Target: $98
Current: $53.49
Upside: +83.21%
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $33.65
Upside: +54.53%
Nov 5, 2024
Reiterates: Outperform
Price Target: $50
Current: $3.67
Upside: +1,264.26%
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $21.98
Upside: +141.13%
Sep 24, 2024
Reiterates: Outperform
Price Target: $30
Current: $7.81
Upside: +284.12%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.00
Upside: +300.00%
Sep 3, 2024
Maintains: Outperform
Price Target: $30,000 → $5,000
Current: $4.20
Upside: +118,947.62%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $5.09
Upside: +391.16%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $3.11
Upside: +543.09%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $21.36
Upside: +35.77%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $18.38
Upside: +90.42%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $0.74
Upside: +1,255.93%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $0.93
Upside: +2,043.62%
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $1.83
Upside: +610.38%
Mar 24, 2023
Maintains: Outperform
Price Target: $150 → $120
Current: $3.81
Upside: +3,049.61%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $9.37
Upside: -
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $19.78
Upside: -
Oct 23, 2020
Initiates: Outperform
Price Target: $50
Current: $1.56
Upside: +3,105.13%
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $18.95
Upside: -